Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer Blackrock
Entity holding fund iShares IV Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF Ticker BTEC(USD) LSE
ETF Ticker BTEK(GBP) LSE
ETF Ticker 2B70(EUR) F
ETF Ticker 2B70.DE(EUR) CXE
ETF Ticker BTEC.LS(USD) CXE
ETF Ticker BTEK.LS(GBP) CXE
ETF Ticker BTEC.L(GBP) LSE
ETF Ticker BTEK.L(GBP) LSE

Holdings detail for ARGX

Stock Name	argenx NV ADR
Ticker	ARGX(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US04016X1019
LEI	7245009C5FZE6G9ODQ71

Show aggregate ARGX holdings

News associated with ARGX

Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts: (RTTNews) - Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives. Amylyx Pharmaceuticals, Amneal Pharmaceuticals, and argenx SE each marked notable gains on Septe - 2025-09-11 06:41:22
Bank of America Raises argenex (NASDAQ:ARGX) Price Target to $887.00: argenex (NASDAQ:ARGX – Get Free Report) had its target price increased by equities researchers at Bank of America from $880.00 to $887.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Bank of America‘s target price would suggest a potential upside of 22.85% from the stock’s […] - 2025-09-04 04:34:49
Wedbush Estimates argenex’s Q3 Earnings (NASDAQ:ARGX): argenex SE (NASDAQ:ARGX – Free Report) – Analysts at Wedbush reduced their Q3 2025 earnings per share (EPS) estimates for argenex in a research report issued to clients and investors on Monday, August 25th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of $5.60 per share for the quarter, down from […] - 2025-08-28 02:22:48
argenex (NASDAQ:ARGX) versus MaxCyte (NASDAQ:MXCT) Head to Head Analysis: MaxCyte (NASDAQ:MXCT – Get Free Report) and argenex (NASDAQ:ARGX – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends. Risk and Volatility MaxCyte has a beta of 1.23, meaning […] - 2025-08-27 04:50:47
argenex (NASDAQ:ARGX) Price Target Raised to $820.00: argenex (NASDAQ:ARGX – Free Report) had its target price raised by Piper Sandler from $750.00 to $820.00 in a research report report published on Tuesday,Benzinga reports. Piper Sandler currently has an overweight rating on the stock. Several other analysts also recently weighed in on ARGX. Oppenheimer lifted their price objective on shares of argenex from […] - 2025-08-27 03:06:44
argenex (NASDAQ:ARGX) Earns “Outperform” Rating from Wedbush: argenex (NASDAQ:ARGX – Get Free Report)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a note issued to investors on Monday,RTT News reports. They currently have a $800.00 target price on the stock. Wedbush’s price objective points to a potential upside of 12.98% from the stock’s previous close. ARGX has been […] - 2025-08-27 02:08:54
argenex (NASDAQ:ARGX) Now Covered by Analysts at Royal Bank Of Canada: Royal Bank Of Canada initiated coverage on shares of argenex (NASDAQ:ARGX – Free Report) in a research report report published on Monday, Marketbeat Ratings reports. The firm issued an outperform rating and a $850.00 price target on the stock. ARGX has been the subject of several other reports. Guggenheim increased their price objective on shares […] - 2025-08-26 03:10:54
Argenx's VYVGART Achieves Primary Endpoint In Pivotal Study For AChR-Ab Seronegative GMG: (RTTNews) - argenx SE (ARGX) reported that the pivotal ADAPT SERON study of VYVGART (IV: efgartigimod alfa-fcab) successfully met its primary endpoint. The study demonstrated a statistically significant and clinically meaningful improvement in MG-ADL (Myasthenia Gravis Activities - 2025-08-25 02:25:55
LPL Financial LLC Has $12.36 Million Position in argenex SE (NASDAQ:ARGX): LPL Financial LLC lifted its holdings in shares of argenex SE (NASDAQ:ARGX – Free Report) by 28.0% during the first quarter, HoldingsChannel reports. The firm owned 20,880 shares of the company’s stock after acquiring an additional 4,563 shares during the quarter. LPL Financial LLC’s holdings in argenex were worth $12,358,000 as of its most recent […] - 2025-08-08 04:28:56
US Bancorp DE Sells 45 Shares of argenex SE (NASDAQ:ARGX): US Bancorp DE decreased its stake in argenex SE (NASDAQ:ARGX – Free Report) by 0.9% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 4,835 shares of the company’s stock after selling 45 shares during the period. US Bancorp DE’s holdings in argenex were worth $2,862,000 as of its most recent filing with the […] - 2025-08-07 05:20:51
argenex SE (NASDAQ:ARGX) Stake Lowered by Avantax Advisory Services Inc.: Avantax Advisory Services Inc. reduced its stake in shares of argenex SE (NASDAQ:ARGX – Free Report) by 5.7% during the 1st quarter, HoldingsChannel reports. The fund owned 1,000 shares of the company’s stock after selling 61 shares during the period. Avantax Advisory Services Inc.’s holdings in argenex were worth $592,000 as of its most recent […] - 2025-08-05 05:52:53
Bank of New York Mellon Corp Buys 7,921 Shares of argenex SE (NASDAQ:ARGX): Bank of New York Mellon Corp raised its holdings in shares of argenex SE (NASDAQ:ARGX – Free Report) by 124.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,283 shares of the company’s stock after buying an additional 7,921 shares […] - 2025-07-23 04:28:43
Ballentine Partners LLC Trims Stock Position in argenex SE (NASDAQ:ARGX): Ballentine Partners LLC lessened its holdings in argenex SE (NASDAQ:ARGX – Free Report) by 7.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 495 shares of the company’s stock after selling 41 shares during the period. Ballentine Partners LLC’s holdings in argenex […] - 2025-07-17 05:33:09
argenex (NASDAQ:ARGX) Upgraded by Deutsche Bank Aktiengesellschaft to Buy Rating: Deutsche Bank Aktiengesellschaft upgraded shares of argenex (NASDAQ:ARGX – Free Report) from a hold rating to a buy rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports. Several other analysts have also recently weighed in on ARGX. HC Wainwright reissued a “buy” rating and issued a $720.00 price target on shares […] - 2025-07-11 02:36:48
2,640 Shares in argenex SE (NASDAQ:ARGX) Acquired by Calamos Advisors LLC: Calamos Advisors LLC purchased a new position in shares of argenex SE (NASDAQ:ARGX – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,640 shares of the company’s stock, valued at approximately $1,563,000. Other hedge funds and other institutional investors have […] - 2025-07-07 06:01:03
argenex (NASDAQ:ARGX) Now Covered by Analysts at Morgan Stanley: Morgan Stanley assumed coverage on shares of argenex (NASDAQ:ARGX – Free Report) in a report published on Thursday morning. The brokerage issued an overweight rating and a $700.00 target price on the stock. A number of other equities analysts have also weighed in on ARGX. Citigroup reiterated a “buy” rating on shares of argenex in […] - 2025-07-04 04:59:45
Implied QQQJ Analyst Target Price: $36: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-03 08:21:16
Janney Montgomery Scott LLC Boosts Stake in argenex SE (NASDAQ:ARGX): Janney Montgomery Scott LLC increased its position in shares of argenex SE (NASDAQ:ARGX – Free Report) by 41.6% during the first quarter, HoldingsChannel reports. The institutional investor owned 1,141 shares of the company’s stock after buying an additional 335 shares during the quarter. Janney Montgomery Scott LLC’s holdings in argenex were worth $675,000 as of […] - 2025-07-02 05:37:06
Sequoia Financial Advisors LLC Boosts Stock Holdings in argenex SE (NASDAQ:ARGX): Sequoia Financial Advisors LLC raised its stake in argenex SE (NASDAQ:ARGX – Free Report) by 1.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,829 shares of the company’s stock after acquiring an additional 24 shares during the period. Sequoia Financial Advisors LLC’s […] - 2025-07-01 05:50:51
Oppenheimer & Co. Inc. Has $542,000 Stock Position in argenex SE (NASDAQ:ARGX): Oppenheimer & Co. Inc. lifted its stake in shares of argenex SE (NASDAQ:ARGX – Free Report) by 10.2% during the first quarter, Holdings Channel.com reports. The firm owned 915 shares of the company’s stock after acquiring an additional 85 shares during the period. Oppenheimer & Co. Inc.’s holdings in argenex were worth $542,000 as of […] - 2025-07-01 05:02:55
argenx SE (NASDAQ:ARGX) Receives Consensus Recommendation of “Buy” from Brokerages: argenx SE (NASDAQ:ARGX – Get Free Report) has been assigned a consensus rating of “Buy” from the twenty-two brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, nineteen have assigned a buy recommendation and two have issued a strong buy recommendation on the company. […] - 2025-06-16 02:52:48
HC Wainwright Reaffirms “Buy” Rating for argenx (NASDAQ:ARGX): argenx (NASDAQ:ARGX – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $720.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 25.23% from the stock’s previous close. A number […] - 2025-06-12 02:18:53
William Blair Estimates argenx’s Q2 Earnings (NASDAQ:ARGX): argenx SE (NASDAQ:ARGX – Free Report) – Analysts at William Blair upped their Q2 2025 earnings estimates for shares of argenx in a note issued to investors on Thursday, May 29th. William Blair analyst M. Minter now expects that the company will earn $2.36 per share for the quarter, up from their previous estimate of […] - 2025-06-03 02:17:11
Analysts Anticipate 10% Upside For FTQI: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-02 07:09:27
argenx SE (NASDAQ:ARGX) Receives Average Recommendation of “Buy” from Brokerages: argenx SE (NASDAQ:ARGX – Get Free Report) has been given an average rating of “Buy” by the twenty-three analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, twenty have given a buy recommendation and two have issued a strong buy recommendation on the […] - 2025-05-22 02:46:43
argenx (NASDAQ:ARGX) Upgraded to Outperform at Robert W. Baird: Robert W. Baird upgraded shares of argenx (NASDAQ:ARGX – Free Report) from a neutral rating to an outperform rating in a report issued on Tuesday, MarketBeat Ratings reports. Robert W. Baird currently has $680.00 price target on the stock. Other analysts have also recently issued research reports about the company. Oppenheimer raised their price objective […] - 2025-05-14 05:36:47
argenx SE (NASDAQ:ARGX) Receives $699.28 Average PT from Analysts: argenx SE (NASDAQ:ARGX – Get Free Report) has been given an average rating of “Moderate Buy” by the twenty-three research firms that are covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to […] - 2025-04-30 02:47:05
Argenx Secures CHMP Recommendation For European Approval Of VYVGART SC Injection For CIDP Treatment: (RTTNews) - argenx SE (ARGX) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended European Commission approval of VYVGART 1000mg (efgartigimod alfa). This subcutaneous (SC) injection is proposed as a monot - 2025-04-28 02:15:50
Analysts Expect FTQI Will Reach $22: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-04-25 07:58:52
Cerity Partners LLC Sells 71 Shares of argenx SE (NASDAQ:ARGX): Cerity Partners LLC cut its stake in shares of argenx SE (NASDAQ:ARGX – Free Report) by 2.2% during the 4th quarter, Holdings Channel reports. The fund owned 3,202 shares of the company’s stock after selling 71 shares during the period. Cerity Partners LLC’s holdings in argenx were worth $1,801,000 as of its most recent SEC […] - 2025-04-17 04:36:51

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) ARGX holdings

Date	Number of ARGX Shares Held	Base Market Value of ARGX Shares	Local Market Value of ARGX Shares	Change in ARGX Shares Held	Change in ARGX Base Value	Current Price per ARGX Share Held	Previous Price per ARGX Share Held
2025-12-04 (Thursday)	22,498	USD 20,607,493	USD 20,607,493
2025-12-03 (Wednesday)	21,478	USD 19,798,420	USD 19,798,420	0	USD 138,318	USD 921.8	USD 915.36
2025-12-02 (Tuesday)	21,478	USD 19,660,102	USD 19,660,102	765	USD 1,124,038	USD 915.36	USD 894.9
2025-12-01 (Monday)	20,713	USD 18,536,064	USD 18,536,064	0	USD -353,778	USD 894.9	USD 911.98
2025-11-28 (Friday)	20,713	USD 18,889,842	USD 18,889,842	51	USD -70,229	USD 911.98	USD 917.63
2025-11-27 (Thursday)	20,662	USD 18,960,071	USD 18,960,071	0	USD 0	USD 917.63	USD 917.63
2025-11-26 (Wednesday)	20,662	USD 18,960,071	USD 18,960,071	153	USD 134,245	USD 917.63	USD 917.93
2025-11-25 (Tuesday)	20,509	USD 18,825,826	USD 18,825,826	255	USD 460,714	USD 917.93	USD 906.74
2025-11-24 (Monday)	20,254	USD 18,365,112	USD 18,365,112	51	USD -199,829	USD 906.74	USD 918.92
2025-11-21 (Friday)	20,203	USD 18,564,941	USD 18,564,941	0	USD 8,485	USD 918.92	USD 918.5
2025-11-20 (Thursday)	20,203	USD 18,556,456	USD 18,556,456	-204	USD -107,582	USD 918.5	USD 914.59
2025-11-19 (Wednesday)	20,407	USD 18,664,038	USD 18,664,038	51	USD -33,559	USD 914.59	USD 918.53
2025-11-18 (Tuesday)	20,356	USD 18,697,597	USD 18,697,597	306	USD 58,916	USD 918.53	USD 929.61
2025-11-17 (Monday)	20,050	USD 18,638,681	USD 18,638,681	102	USD 526,296	USD 929.61	USD 907.98

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ARGX by Blackrock for IE00BYXG2H39

Show aggregate share trades of ARGX

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-02 BUY 765 919.820 902.370 904.115 USD 691,648 648.68
2025-11-28 BUY 51 916.510 905.225 906.353 USD 46,224 646.30
2025-11-26 BUY 153 928.990 915.360 916.723 USD 140,259 643.74
2025-11-26 BUY 153 928.990 915.360 916.723 USD 140,259 643.74
2025-11-25 BUY 255 920.160 900.160 902.160 USD 230,051 642.44
2025-11-24 BUY 51 918.310 897.500 899.581 USD 45,879 641.18
2025-11-20 SELL -204 932.180 912.920 914.846 USD -186,629 638.51 Loss of -56,372 on sale
2025-11-19 BUY 51 928.120 912.570 914.125 USD 46,620 637.18
2025-11-18 BUY 306 929.800 908.160 910.324 USD 278,559 635.81
2025-11-17 BUY 102 933.900 910.020 912.408 USD 93,066 634.38
2025-11-14 BUY 51 914.870 880.970 884.360 USD 45,102 633.04
2025-11-12 BUY 51 907.470 885.810 887.976 USD 45,287 630.49
2025-11-10 BUY 51 872.910 852.390 854.442 USD 43,577 627.99
2025-11-06 BUY 51 855.700 831.460 833.884 USD 42,528 625.72
2025-11-04 BUY 51 850.660 824.700 827.296 USD 42,192 623.62
2025-10-30 BUY 255 830.495 749.750 757.824 USD 193,245 620.54
2025-10-29 BUY 146 821.970 842.185 840.163 USD 122,664 619.49
2025-10-22 SELL -204 814.170 839.660 837.111 USD -170,771 614.08 Loss of -45,499 on sale
2025-10-20 BUY 102 849.460 855.460 854.860 USD 87,196 611.61
2025-10-17 BUY 255 843.660 849.990 849.357 USD 216,586 610.35
2025-10-15 BUY 408 815.610 819.710 819.300 USD 334,274 609.23
2025-10-03 BUY 350 800.000 803.740 803.366 USD 281,178 607.05
2025-10-02 BUY 50 791.590 793.470 793.282 USD 39,664 606.02
2025-09-30 BUY 100 737.560 741.050 740.701 USD 74,070 604.38
2025-09-26 BUY 100 711.620 720.820 719.900 USD 71,990 603.12
2025-09-25 BUY 100 711.090 723.250 722.034 USD 72,203 602.50
2025-09-24 SELL -1,467 729.760 734.950 734.431 USD -1,077,410 601.77 Loss of -194,616 on sale
2025-09-18 BUY 54 731.770 737.870 737.260 USD 39,812 601.02
2025-09-17 BUY 165 734.350 755.665 753.533 USD 124,333 600.24
2025-08-20 SELL -220 660.970 661.710 661.636 USD -145,560 597.93 Loss of -14,015 on sale
2025-07-30 BUY 276 598.890 608.280 607.341 USD 167,626 596.23
2025-07-17 SELL -108 572.710 573.480 573.403 USD -61,928 597.14 Profit of 2,563 on sale
2025-07-16 BUY 183 577.920 578.315 578.276 USD 105,824 597.26
2025-07-11 SELL -432 560.240 564.025 563.647 USD -243,495 598.03 Profit of 14,854 on sale
2025-07-07 BUY 162 546.040 546.730 546.661 USD 88,559 599.33
2025-07-02 BUY 2,970 545.110 554.395 553.467 USD 1,643,796 600.10
2025-06-20 BUY 191 542.150 546.910 546.434 USD 104,369 600.51
2025-06-13 BUY 47 577.890 583.160 582.633 USD 27,384 602.39
2025-06-11 BUY 106 574.960 582.011 581.306 USD 61,618 602.71
2025-06-10 BUY 106 575.460 589.900 588.456 USD 62,376 602.91
2025-06-04 SELL -53 573.505 585.215 584.044 USD -30,954 603.59 Profit of 1,036 on sale
2025-04-23 BUY 53 594.650 603.150 602.300 USD 31,922 607.25
2025-04-10 SELL -424 546.220 564.790 562.933 USD -238,684 608.91 Profit of 19,493 on sale
2025-04-08 SELL -53 548.930 577.415 574.566 USD -30,452 610.08 Profit of 1,882 on sale
2025-04-07 SELL -53 550.000 560.348 559.313 USD -29,644 610.77 Profit of 2,727 on sale
2025-04-04 SELL -265 555.110 582.723 579.962 USD -153,690 611.41 Profit of 8,333 on sale
2025-04-01 BUY 454 567.090 593.990 591.300 USD 268,450 612.25
2025-03-31 SELL -156 591.865 594.420 594.164 USD -92,690 612.50 Profit of 2,860 on sale
2025-03-21 BUY 535 615.020 619.920 619.430 USD 331,395 613.53
2025-03-14 SELL -800 604.960 605.430 605.383 USD -484,306 613.58 Profit of 6,561 on sale
2025-03-07 SELL -100 594.210 612.400 610.581 USD -61,058 615.79 Profit of 520 on sale
2025-03-04 SELL -50 621.250 633.640 632.401 USD -31,620 615.42 Loss of -849 on sale
2025-02-25 BUY 100 624.940 636.390 635.245 USD 63,525 614.71
2025-02-19 SELL -50 640.140 645.025 644.537 USD -32,227 612.93 Loss of -1,580 on sale
2025-02-13 BUY 150 651.340 652.230 652.141 USD 97,821 610.68
2025-02-12 BUY 50 649.090 649.960 649.873 USD 32,494 609.92
2025-02-11 BUY 200 636.020 647.205 646.087 USD 129,217 609.40
2025-01-02 BUY 39 620.160 627.800 627.036 USD 24,454 592.90
2024-12-30 SELL -1,733 619.960 625.930 625.333 USD -1,083,702 592.13 Loss of -57,538 on sale
2024-11-18 SELL -825 567.900 569.420 569.268 USD -469,646 574.83 Profit of 4,589 on sale
2024-11-08 SELL -55 596.000 599.400 599.060 USD -32,948 571.95 Loss of -1,491 on sale
2024-10-21 SELL -55 560.450 565.160 564.689 USD -31,058 0.00 Loss of -31,058 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-02	BUY	765	919.820	902.370	904.115	USD 691,648	648.68
2025-11-28	BUY	51	916.510	905.225	906.353	USD 46,224	646.30
2025-11-26	BUY	153	928.990	915.360	916.723	USD 140,259	643.74
2025-11-26	BUY	153	928.990	915.360	916.723	USD 140,259	643.74
2025-11-25	BUY	255	920.160	900.160	902.160	USD 230,051	642.44
2025-11-24	BUY	51	918.310	897.500	899.581	USD 45,879	641.18
2025-11-20	SELL	-204	932.180	912.920	914.846	USD -186,629	638.51 Loss of -56,372 on sale
2025-11-19	BUY	51	928.120	912.570	914.125	USD 46,620	637.18
2025-11-18	BUY	306	929.800	908.160	910.324	USD 278,559	635.81
2025-11-17	BUY	102	933.900	910.020	912.408	USD 93,066	634.38
2025-11-14	BUY	51	914.870	880.970	884.360	USD 45,102	633.04
2025-11-12	BUY	51	907.470	885.810	887.976	USD 45,287	630.49
2025-11-10	BUY	51	872.910	852.390	854.442	USD 43,577	627.99
2025-11-06	BUY	51	855.700	831.460	833.884	USD 42,528	625.72
2025-11-04	BUY	51	850.660	824.700	827.296	USD 42,192	623.62
2025-10-30	BUY	255	830.495	749.750	757.824	USD 193,245	620.54
2025-10-29	BUY	146	821.970	842.185	840.163	USD 122,664	619.49
2025-10-22	SELL	-204	814.170	839.660	837.111	USD -170,771	614.08 Loss of -45,499 on sale
2025-10-20	BUY	102	849.460	855.460	854.860	USD 87,196	611.61
2025-10-17	BUY	255	843.660	849.990	849.357	USD 216,586	610.35
2025-10-15	BUY	408	815.610	819.710	819.300	USD 334,274	609.23
2025-10-03	BUY	350	800.000	803.740	803.366	USD 281,178	607.05
2025-10-02	BUY	50	791.590	793.470	793.282	USD 39,664	606.02
2025-09-30	BUY	100	737.560	741.050	740.701	USD 74,070	604.38
2025-09-26	BUY	100	711.620	720.820	719.900	USD 71,990	603.12
2025-09-25	BUY	100	711.090	723.250	722.034	USD 72,203	602.50
2025-09-24	SELL	-1,467	729.760	734.950	734.431	USD -1,077,410	601.77 Loss of -194,616 on sale
2025-09-18	BUY	54	731.770	737.870	737.260	USD 39,812	601.02
2025-09-17	BUY	165	734.350	755.665	753.533	USD 124,333	600.24
2025-08-20	SELL	-220	660.970	661.710	661.636	USD -145,560	597.93 Loss of -14,015 on sale
2025-07-30	BUY	276	598.890	608.280	607.341	USD 167,626	596.23
2025-07-17	SELL	-108	572.710	573.480	573.403	USD -61,928	597.14 Profit of 2,563 on sale
2025-07-16	BUY	183	577.920	578.315	578.276	USD 105,824	597.26
2025-07-11	SELL	-432	560.240	564.025	563.647	USD -243,495	598.03 Profit of 14,854 on sale
2025-07-07	BUY	162	546.040	546.730	546.661	USD 88,559	599.33
2025-07-02	BUY	2,970	545.110	554.395	553.467	USD 1,643,796	600.10
2025-06-20	BUY	191	542.150	546.910	546.434	USD 104,369	600.51
2025-06-13	BUY	47	577.890	583.160	582.633	USD 27,384	602.39
2025-06-11	BUY	106	574.960	582.011	581.306	USD 61,618	602.71
2025-06-10	BUY	106	575.460	589.900	588.456	USD 62,376	602.91
2025-06-04	SELL	-53	573.505	585.215	584.044	USD -30,954	603.59 Profit of 1,036 on sale
2025-04-23	BUY	53	594.650	603.150	602.300	USD 31,922	607.25
2025-04-10	SELL	-424	546.220	564.790	562.933	USD -238,684	608.91 Profit of 19,493 on sale
2025-04-08	SELL	-53	548.930	577.415	574.566	USD -30,452	610.08 Profit of 1,882 on sale
2025-04-07	SELL	-53	550.000	560.348	559.313	USD -29,644	610.77 Profit of 2,727 on sale
2025-04-04	SELL	-265	555.110	582.723	579.962	USD -153,690	611.41 Profit of 8,333 on sale
2025-04-01	BUY	454	567.090	593.990	591.300	USD 268,450	612.25
2025-03-31	SELL	-156	591.865	594.420	594.164	USD -92,690	612.50 Profit of 2,860 on sale
2025-03-21	BUY	535	615.020	619.920	619.430	USD 331,395	613.53
2025-03-14	SELL	-800	604.960	605.430	605.383	USD -484,306	613.58 Profit of 6,561 on sale
2025-03-07	SELL	-100	594.210	612.400	610.581	USD -61,058	615.79 Profit of 520 on sale
2025-03-04	SELL	-50	621.250	633.640	632.401	USD -31,620	615.42 Loss of -849 on sale
2025-02-25	BUY	100	624.940	636.390	635.245	USD 63,525	614.71
2025-02-19	SELL	-50	640.140	645.025	644.537	USD -32,227	612.93 Loss of -1,580 on sale
2025-02-13	BUY	150	651.340	652.230	652.141	USD 97,821	610.68
2025-02-12	BUY	50	649.090	649.960	649.873	USD 32,494	609.92
2025-02-11	BUY	200	636.020	647.205	646.087	USD 129,217	609.40
2025-01-02	BUY	39	620.160	627.800	627.036	USD 24,454	592.90
2024-12-30	SELL	-1,733	619.960	625.930	625.333	USD -1,083,702	592.13 Loss of -57,538 on sale
2024-11-18	SELL	-825	567.900	569.420	569.268	USD -469,646	574.83 Profit of 4,589 on sale
2024-11-08	SELL	-55	596.000	599.400	599.060	USD -32,948	571.95 Loss of -1,491 on sale
2024-10-21	SELL	-55	560.450	565.160	564.689	USD -31,058	0.00 Loss of -31,058 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ARGX

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	72,763	2,502	307,243	23.7%
2025-09-18	66,114	100	178,136	37.1%
2025-09-17	51,296	0	135,160	38.0%
2025-09-16	45,933	25	100,558	45.7%
2025-09-15	42,956	1	110,022	39.0%
2025-09-12	38,767	5	69,609	55.7%
2025-09-11	71,587	18	148,576	48.2%
2025-09-10	55,217	0	107,930	51.2%
2025-09-09	99,902	0	145,247	68.8%
2025-09-08	100,521	0	142,656	70.5%
2025-09-05	103,290	0	193,139	53.5%
2025-09-04	98,380	202	204,613	48.1%
2025-09-03	86,149	0	197,391	43.6%
2025-09-02	41,152	170	125,433	32.8%
2025-08-29	73,309	1,415	119,292	61.5%
2025-08-28	42,581	1	121,588	35.0%
2025-08-27	67,163	0	120,309	55.8%
2025-08-26	125,095	0	179,947	69.5%
2025-08-25	125,620	120	232,991	53.9%
2025-08-22	49,311	0	80,119	61.5%
2025-08-21	71,510	130	141,799	50.4%
2025-08-20	50,903	30	98,830	51.5%
2025-08-19	76,985	1,806	163,664	47.0%
2025-08-18	79,159	519	108,694	72.8%
2025-08-15	58,487	1	143,510	40.8%
2025-08-14	47,422	10	80,907	58.6%
2025-08-13	54,712	0	153,626	35.6%
2025-08-12	52,486	0	137,478	38.2%
2025-08-11	70,367	0	313,405	22.5%
2025-08-08	47,096	2,281	124,062	38.0%
2025-08-07	51,435	1	141,961	36.2%
2025-08-06	66,887	2,216	147,777	45.3%
2025-08-05	62,106	1	155,239	40.0%
2025-08-04	90,332	45	168,641	53.6%
2025-08-01	130,416	135	306,438	42.6%
2025-07-31	204,678	150	579,990	35.3%
2025-07-30	132,061	285	207,878	63.5%
2025-07-29	49,591	188	93,315	53.1%
2025-07-28	91,517	869	124,338	73.6%
2025-07-25	108,659	742	208,296	52.2%
2025-07-24	51,767	47	191,336	27.1%
2025-07-23	41,977	0	83,178	50.5%
2025-07-22	41,167	135	75,074	54.8%
2025-07-21	41,112	32	65,379	62.9%
2025-07-18	51,292	153	83,421	61.5%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	BTEC(USD) LSE
ETF Ticker	BTEK(GBP) LSE
ETF Ticker	2B70(EUR) F
ETF Ticker	2B70.DE(EUR) CXE
ETF Ticker	BTEC.LS(USD) CXE
ETF Ticker	BTEK.LS(GBP) CXE
ETF Ticker	BTEC.L(GBP) LSE
ETF Ticker	BTEK.L(GBP) LSE